Background: After acute myocardial infarction (AMI), patients with a history of arterial hypertension (AH) have a worse prognosis than normotensives. Whether this adverse risk is beneficially modulated by treatment with angiotensin-converting enzyme (ACE) inhibitors is unknown. We evaluated the prognostic value of antecedent hypertension in post-AMI patients given ACE inhibitor therapy. Methods: We analysed retrospectively data from the AIRE study (randomised, placebo-controlled trial of ramipril in 2006 post-AMI patients with clinical heart failure). A history of AH was present in 28% of the patients. We examined the prognostic value of antecedent hypertension separately among placebo and ramipril treated patients and also the effect of ramipril on clinical outcomes according to whether or not a history of AH was present.
Introduction
Hypertension is a major contributor to atherosclerotic cardiovascular disease. Furthermore, coronary heart disease is the most common and lethal cardiovascular sequel to hypertension, though pharmacological treatment can help to reduce the risk of myocardial infarction among hypertensive patients. 1 Not only does a history of hypertension help to predict the development of coronary artery disease, but it also indicates a poorer prognosis after acute myocardial infarction (AMI). Several studies performed in the previous decade demonstrated that a history of antecedent hypertension is a negative independent prognostic factor after AMI. [2] [3] [4] [5] In addition, the deleterious effect of a history of hypertension in post-AMI patients is highlighted by the fact that it increases the mortality risk at all levels of left ventricular (LV) ejection fraction and pulmonary con-gestion. 6 However, it is unknown whether antecedent hypertension retains its negative prognostic influence in contemporary post-AMI patients routinely treated with angiotensin-converting enzyme (ACE) inhibitor therapy.
ACE inhibition is an effective antihypertensive therapy that also substantially improves long-term survival of patients with evidence of LV dysfunction after AMI. [7] [8] [9] ACE inhibitors therefore have the potential to be of particular clinical benefit in post-AMI patients with antecedent hypertension through several mechanisms. The main effect is likely to relate to prevention or attenuation of adverse ventricular remodelling and infarct expansion, which is more pronounced in patients with prior hypertension. 10 Lowering of blood pressure per se might also be advantageous in these patients, though experience with vasodilating calcium antagonists suggests that such a mechanism is not dominant.
11
The AIRE study was one of the landmark studies to demonstrate the value of ACE inhibition in patients with AMI and some evidence of LV dysfunction. In the current investigation we evaluated the prognostic value of a history of hypertension in the placebo and ramipril treated cohorts of patients. We also assessed whether a history of antecedent hypertension affected the efficacy of the ACE inhibitor ramipril in improving clinical outcomes.
Patients and methods
The design and results of the AIRE study have been published previously. 8, 12 Briefly, this was a randomised, double-blind, placebo-controlled trial. Patients were eligible for inclusion if they had a definite AMI and clinical evidence of transient or persistent heart failure (HF) (S3 gallop and/or radiographic and/or clinical evidence of pulmonary venous congestion) at any time from hospital admission to randomisation. Exclusion criteria were recognised contraindications to ACE inhibitor treatment, HF of primary valvular or congenital etiology and unstable angina. Patients with severe HF (usually NYHA grade IV) and on ACE inhibitors or about to start treatment with an ACE inhibitor were also excluded. One thousand and four (1004) patients were randomised to receive ramipril and 982 to receive placebo, starting from Day 2 to Day 9 after the index AMI (Day 0). Follow-up was for a minimum of 6 months and an average of 15 months.
A history of hypertension was considered to be present where patients had previously been informed of a diagnosis of hypertension for which specific pharmaceutical antihypertensive therapy was still being taken. At the time of the index AMI a history of hypertension was present in 554 (28%) of the AIRE study patients.
The most important end-points in the AIRE study were all-cause mortality (primary) and severe/ resistant heart failure (SRHF) (secondary). In addition, two modes of death were examined in the current analysis: sudden cardiac and circulatory failure death. Details about definitions and classification of mode of death in the AIRE study are described elsewhere. 13 SRHF was prospectively defined as: clinical judgment of severe heart failure (usually NYHA grade IV) that is unresponsive to non-ACE inhibitor treatment. Onset was usually the date at which open-label ACE inhibitor treatment started.
Statistical analyses
Baseline characteristics of normotensive and hypertensive patients were compared using two-sample ttests for continuous variables and chi-squared tests for categorical variables. The mortality and other risks associated with antecedent hypertension were examined separately for patients randomly allocated either placebo or ramipril therapy. The effect of ramipril therapy on mortality among normotensive and hypertensive patients was also examined. Relative risks and confidence intervals were derived from unadjusted and multivariate Cox proportional hazards models. To test formally whether hypertensive patients responded differently to ramipril than normotensive patients the statistical interaction between a history of hypertension and the effect of ramipril therapy was fitted into the Cox models. All P values are two-tailed, and a significance level of 0.05 was used. Statistical analyses were performed using SPSS version 6.1.
Results
Randomly allocated placebo and ramipril patient groups were matched in all aspects at baseline. 8 In contrast, the clinical and historical characteristics of patient cohorts with and without a history of hypertension differed, and are displayed in Table 1 . On average hypertensives were older and the proportion of females greater. Furthermore, a history of hypertension was more commonly associated with a past medical history of AMI, angina, heart failure, cardiac arrhythmias and diabetes mellitus. Not surprisingly, hypertensives were less likely to have received thrombolytic therapy at the time of the index AMI, and were more likely to have been receiving a calcium antagonist at randomisation. Hypertensive patients were also more likely to be discharged on no trial medication [40(15. 
Prognostic value of hypertension
A history of hypertension was a significant predictor of all-cause mortality risk (Hazard Ratio 1.32, 95% Confidence Intervals 1.07 to 1.63, P = 0.009) and SRHF occurrence (HR 1.32, 95% CI 1.05 to 1.67, P = 0.019) in the AIRE study before adjusting for other variables. In a similar way, antecedent hypertension was a significant predictor of the sudden death risk (HR 1.54, 95% CI 1.17 to 2.05, P = 0.003). In contrast, it did not appear to be predictive of circulatory death (HR 1.10, 95% CI 0.77 to 1.59, P = 0.6).
Among placebo treated patients, antecedent hypertension was a significant predictor of mortality risk (HR 1.49, 95% CI 1.13 to 1.97, P = 0.005; Figure 1a ), SRHF occurrence (HR 1.48, 95% CI 1.08 to 2.03, P = 0.014) and sudden death incidence (HR 1.75, 95% CI 1.21 to 2.54, P = 0.003). Among the patients treated with ramipril the hazard ratios were lower for all three outcomes, and a history of hypertension was not a significant predictor of mortality risk (HR 1.17, 95% CI 0.84 to 1.61, P = 0.34; Figure 1b ), SRHF occurrence (HR 1.18, 95% CI 0.83 to 1.68, P = 0.37) or sudden death incidence (HR 1.34, 95% CI 0.86 to 2.07, P = 0.18). As was the case in the entire study population, antecedent hypertension did not have any value in predicting circulatory failure death risk in either of these two groups of patients.
Ramipril effects in subgroups defined by the presence of antecedent hypertension
Compared to placebo ramipril therapy reduced the absolute all-cause mortality in both normotensive When the mode of death was considered, treatment with ramipril resulted in a reduction of the sudden death risk in both hypertensives (10.7% vs 17.0%; HR 0.60, 95% CI 0.38 to 0.95, P = 0.03) and normotensives (8.1% vs 10.6%; HR 0.77, 95% CI 0.55 to 1.09, P = 0.14), though this effect was significant only in the former group of patients. Treatment with ramipril was not associated with a significant reduction of the circulatory death risk in any group of patients (hypertensives: HR 0.86, 95% CI 0.47 to 1.58, P = 0.63; normotensives: HR 0.80, 95% CI 0.54 to 1.18, P = 0.26). However, the power of both of these analyses was low so they should be interpreted cautiously.
Multivariable analysis
In view of the distinct differences in the baseline characteristics between those with and without a history of hypertension, a multivariate analysis adjusting for all these factors was conducted to further evaluate the relative effect of ramipril therapy on the mortality risk within the two groups. The adjusted hazard ratios remained essentially unaltered, and ramipril therapy was an independent predictor of improved survival outcome in the hypertensive patients (HR 0.64, 95% CI 0.45 to 0.92, P = 0.016), and maintained its effect, although weaker, in the normotensive patients (HR 0.79, 95% CI 0.61 to 1.01, P = 0.056).
Although in both the above analyses the mortality benefit point estimates were clearly larger in the hypertensive patients, the statistical interaction between the benefit of ramipril therapy and a history of hypertension in both the univariate ( 2 = 1.11 on 1 degree of freedom, P = 0.2) and multivariate analysis ( 2 = 0.07 on 1 degree of freedom, P = 0.4) was not significant. This implies that normotensives and hypertensives do not respond differently to ACE inhibitor therapy.
Discussion
The principal finding of this analysis was that for patients with AMI and clinical heart failure the risk associated with antecedent hypertension was not demonstrable in patients given ACE inhibitor therapy. The significant prognostic effect of antecedent hypertension shown to be present in many post-AMI populations in the past could not be demonstrated in our ACE inhibitor treated post-AMI population. When patients were prescribed an ACE inhibitor their prognosis was substantially improved and their risk profile changed to a point that it was not significantly different from that of normotensive patients. In addition our data indicate that both hypertensive and normotensive patients benefited from ACE inhibitor treatment. The test for interaction between ramipril therapy and a history of hypertension in the mortality analysis was not statistically significant, suggesting that normotensives and hypertensives respond similarly to ACE inhibitor therapy.
Prognostic value of antecedent hypertension after AMI
The independent negative prognostic value of antecedent hypertension after initial AMI has been well established by many studies carried out in both consecutive and selected post-AMI populations. [2] [3] [4] [5] Of relevance to the AIRE study population is the observation that a history of hypertension increases the mortality risk at all levels of left ventricular ejection fraction and pulmonary congestion after AMI. 6 However, these associations were established by studies that had been conducted before the routine use of ACE inhibitors.
When the entire AIRE study population was considered, antecedent hypertension was a significant negative univariate prognostic factor. Whereas hypertension was an important predictor of mortality in placebo treated patients, it was not a significant predictor of mortality in patients given ACE inhibitor therapy.
In a similar fashion, with respect to the mode of death and SRHF analysis, antecedent hypertension was a powerful predictor of sudden death and SRHF occurrence in the entire AIRE study population and the placebo treated patients. However, any such association was weak and not statistically significant in the ramipril treated patients. These results suggest that the excess risk associated with a history of hypertension may be beneficially modulated by treatment with ACE inhibitors after AMI.
The possibility that a substantially larger study might show that the above association still holds even with ACE inhibitor treatment cannot be discarded. Our study however, was by no means lacking in power compared with previous studies of this relationship before the introduction of ACE inhibitor treatment. The statistical power of our analysis to detect an adverse effect of antecedent hypertension on the mortality risk within the ACE inhibitor treatment arm was larger than all 2-4,6 but one 5 of the milestone studies that confirmed this association in the past.
ACE inhibition: benefits in hypertensive and normotensive patients
Although both hypertensive and normotensive patients benefited from ACE inhibitor therapy, the magnitude of the relative risk reductions produced by ramipril therapy on several clinical outcomes appeared to be larger in the hypertensive patients as compared to those attained in normotensive patients. An important issue in sub-group analysis is that the subgroups should be truly comparable. If they are not, as was the case with the hypertensive/normotensive subgroups, regression methods can be used to adjust for imbalances in prognostic factors between the groups. 14 In keeping with our main analysis, in our multivariate model the magnitude of the effect of ramipril therapy was larger in the hypertensive group of patients.
In other ACE inhibitor post-AMI trials, where findings in these subgroups have been reported, hypertensive patients similarly appear to have benefited from larger relative risk reductions as compared to normotensives. In the TRACE study treatment with trandolapril in patients with reduced left ventricular systolic function after AMI resulted in a 41% mortality risk reduction in hypertensive patients and only in a 15% risk reduction in normotensives. 15 In the SMILE study, the relative risk of death or progression to severe congestive heart failure for patients who had suffered an anterior AMI and were allocated to the ACE inhibitor, zofenapril, or placebo was reduced by 47% for hypertensives and only 13% for normotensives. 16 In contrast to these studies, the SAVE study investigators reported the relative mortality risk reduction in the hypertensive compared with the normotensive group of patients to be only marginally higher (20% vs 19%). 17 Only the TRACE study investigators have published a dedicated subgroup analysis with respect to the presence of a history of hypertension. 15 Interestingly, in this study the interaction between ACE inhibitor therapy and antecedent hypertension was statistically significant (P Ͻ 0.001) indicating that hypertensives benefited significantly more from ACE inhibitor therapy than normotensives. Not only was the mortality reduction produced by ACE inhibitor therapy in this study greater in hypertensives than normotensives but it was also statistically significant only in hypertensives (HR 0.59, 95% CI 0.44 to 0.80, P Ͻ 0.001) and not in the normotensive patients (HR 0.85, 95% CI 0.72 to 1.02, P = 0.08).
In the context of a trial in which the overall effect of the tested treatment is significantly positive, the most likely explanation of failure to observe a significant benefit within a subgroup is a type II error due to low power. 18, 19 A well-designed clinical trial uses the least number of patients to give a decisive result. Because subgroup analyses always include fewer patients than the trial as a whole, they have a lower statistical power to detect the treatment effect attained in the entire trial population and the risk of falsely concluding that the null hypothesis is true (type II error) is therefore increased. If benefit from a treatment is statistically significant for a trial as a whole and the benefit is of a similar degree in all subgroups, then it is very likely that it is also beneficial in a subgroup in which statistical significance has not been achieved.
The consistency in the finding that hypertensives exhibit larger relative risk reductions with ACE inhibitor therapy across many similar large studies is strongly indicative that hypertensives have more to gain from treatment with an ACE inhibitor in terms of relative mortality reduction. Of course as a high risk group of patients there is no doubt that they also gain more in terms of absolute mortality reduction.
Biological plausibility: reduction of infarct expansion and adverse remodelling
A differential response to a treatment found in a subgroup analysis is more readily believable if it is biological plausible. 19, 20 Among the many effects of ACE inhibition, some may assume particular merit among post-AMI patients who have a history of hypertension and might explain the observed enhanced benefits produced by ACE inhibition in this group of patients. This might also explain the elimination of a history of hypertension as a significant risk factor among post-AMI patients prescribed with ACE inhibitor therapy. Previous history of hypertension, which is a major determinant of the ventricular afterload, is a strong predictor of infarct expansion, 10 which in turn is directly related to increased mortality and heart failure morbidity. 21 ACE inhibition prevents or attenuates infarct expansion 22 and thus would be expected to be particularly advantageous in hypertensive patients.
Ventricular hypertrophy, a common feature of hypertension, is associated with ventricular arrhythmias and sudden death and represents an adverse prognostic factor. 23, 24 Our own data show a direct association between a history of hypertension and sudden death after AMI. Therefore, ACE inhibition can also be of particular importance in hypertensives by inducing regression of pre-existing left ventricular hypertrophy and preventing the development of hypertrophy of the non-infarcted muscle as part of the remodelling process. 25, 26 The efficacy of ramipril in reducing the sudden death risk in hypertensives may be related to this mechanism. There is also evidence that endothelial dysfunction, a common feature of hypertension, 27 is improved or reversed by ACE inhibition. 28 This might be an additional beneficial mechanism operating in hypertensive patients.
Conclusion
In conclusion, our data indicate that for post-AMI patients given ACE inhibitor therapy, a history of hypertension is not a significant marker of worse prognosis. Furthermore, ACE inhibitor therapy is beneficial in post-AMI patients with clinical HF, irrespective of whether or not a history of hypertension is present. The data support the concept that this therapy is particularly efficacious in improving clinical outcomes in patients with antecedent hypertension.
